News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Affymax, Inc. (AFFY) and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Release: OMONTYS┬« (Peginesatide) Injection Now Available for Adult Chronic Kidney Disease (CKD) Patients on Dialysis in the United States



4/24/2012 9:07:57 AM

PALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Affymax, Inc. (NASDAQ:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that OMONTYS® (peginesatide) Injection is now available only for use in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population in the United States. OMONTYS is co-marketed by Affymax and Takeda Pharmaceuticals U.S.A. (TPUSA) and distributed by TPUSA. See below for Full Indication, Limitations of Use and Important Safety Information including Boxed WARNINGS.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES